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Abstract 10 
Multidrug efflux pumps confer resistance to their bacterial hosts by pumping out a diverse 11 
range of compounds, including most antibiotics. Being more familiar with the details of 12 
functional dynamics and conformations of these types of pumps could help in discovering 13 
approaches to stop them functioning properly. Computational approaches, particularly 14 
conventional molecular dynamics simulations followed by diverse post simulation analysis, 15 
are powerful methods that help researchers by opening a new window to study phenomena 16 
that are not detectable in as much detail in vitro or in vivo as they are in silico. In this study, 17 
accelerated molecular dynamics simulations were applied to study the dynamics of AcrB 18 
efflux pump transporters in interaction with PAβN and tetracycline as an inhibitor and a 19 
substrate, respectively, to compare the differences in the dynamics and consequently the 20 
mechanism of action of the pump. The different dynamics for PaβN -bound form of AcrB 21 
compared to the Tet-bound form is likely to affect the rotating mechanism typically 22 
observed for AcrB transporter. This shows the dynamics of the active AcrB transporter is 23 
different in a substrate-bound state compared to an inhibitor-bound state. This advances 24 
our knowledge and helps to unravel the mechanism of tripartite efflux pumps.  25 
 26 
 27 
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 33 
Introduction 34 
Overexpression of the resistance nodulation cell division (RND) type of tripartite efflux 35 
pumps in the Gram-negative pathogens is a major component of multidrug resistance 36 
(MDR) 1. These types of efflux pumps recognize a diverse range of compounds and pump 37 
them out from the bacteria cell via proton-motive force (PMF) secondary transporters like 38 
AcrB, part of AcrAB-TolC efflux pump, present in Klebsiella pneumoniae and Escherichia coli2-39 
8.  40 
The substrate specificity and selectivity of AcrAB-TolC efflux pump depends on the 41 
homotrimer structure of AcrB, with threefold asymmetric conformation, in which each 42 
monomer adopts a different conformation, access, binding and extrusion5,9-14. AcrB of K. 43 
pneumoniae, that has similar sequence to the solved crystal structure of AcrB of E. coli, 44 
pumps out the compounds employing a rotating mechanism that is allosterically coupled, in 45 
which each monomer successively adopts one of the three conformations10,11,14-20.  Recent 46 
computational works have further shed lights on the relationship between functional 47 
rotation and substrate transport21-23. Structures with bound drugs revealed two discrete 48 
multisite binding pockets separated by a switch loop, with the distal pocket in the binding 49 
(tight) state and a proximal pocket in the structure24,25 (Fig. 1). The proximal and distal 50 
binding pockets that are involved in forming the multibinding site of AcrB, as the substrate-51 
selective part of the pump, play key roles in its specificity and binding to substrates2,24-32. 52 
The G-loop controls the access of substrates to the distal pocket by forming a boundary 53 
between the proximal and distal binding pockets2. Under the G-loop, there is a narrow 54 
channel that connects proximal and distal pockets to each other (Fig. 1). The pockets are 55 
enriched in aromatic, polar and charged amino acid residues that form favourable 56 
interactions with the transported substrates. The microenvironment of the distal binding 57 
pocket within AcrB has been studied in detail33,34. Since the distal binding pocket includes 58 
many hydrophobic, polar and charged residues, this microenvironment mediates extrusion 59 
of a wide range of compounds by AcrB4,35,36. Based on the multisite-drug-oscillation 60 
hypothesis by Yamaguchi8, the spacious multidrug-binding pocket may have numerous 61 
binding sites even for a single substrate, suggesting that substrates may move between 62 
binding sites during transport. This hypothesis could explain the apparently broad substrate 63 
specificity of cell membrane exporters and their highly efficient ejection of drugs from the 64 
bacteria cells.  65 
 66 
Substrates that are taken up from the entrance ports, in particular the cleft, of an efflux 67 
pump could be transported through dual multidrug-binding pockets by a peristaltic 68 
mechanism at the substrate translocation channel37 through both proximal and distal 69 
pockets, and could be potentially extruded from the top exit port. Actually, the asymmetric 70 
trimer is supportive of a rotating access mechanism for drug binding and release (Fig. S1).  71 
Designing effective inhibitors to stop these types of pumps from effluxing out antibiotics 72 
requires an understanding of the functional dynamics and molecular mechanisms of 73 
conformational changes of this type of protein. There are only a few solved structures for 74 
AcrB of E. coli in complex with different compounds10,20,25,38 and no structure for AcrB of K. 75 
pneumoniae. 76 
 77 
Conventional molecular dynamics (cMD) simulations  enable  simulations on the order of 78 
tens to hundreds of nanoseconds; however, longer simulations are required to monitor 79 
biological processes that typically occur on longer time scales of up to milliseconds or 80 
more39. Recently developed advanced sampling techniques such as accelerated molecular 81 
dynamics (aMD) simulations allows access  to these longer time scale molecular events 82 
beyond those obtainable with cMD40,41. aMD reduces the height of local barriers which 83 
allows faster calculations and time efficient simulation of biomacromolecules42. It simplifies 84 
the sampling by requiring only the evolution of a single copy of the system and does  not 85 
require any previous knowledge of the shape of the potential energy profile39. 86 
 87 
aMD simulations allow determination of  time-dependent protein conformational changes 88 
which enables sampling the conformational space more efficiently than conventional 89 
molecular dynamics simulations43-48 and has been fully integrated into commonly used 90 
software such as Amber39,49. Advanced sampling techniques employed by aMD extend the 91 
time scale of MD simulations that converges the correct canonical probability distribution 92 
and enables rapid sampling of the conformational space42.  93 
 94 
Nikaido et al. in their recent works2,50,51 studied a truncated model of AcrB transporter from 95 
E. coli in interaction with different ligands by cMD simulations. This showed the important 96 
role of the G- loop and the deep hydrophobic groove of the distal site, indicating that the 97 
binding mode of compounds to the transporter alters the efflux of other substrates. 98 
Similarly, Fischer and Kandt studied the conformational changes in the porter domain of 99 
AcrB from E. Coli conventional molecular dynamics52. In this study, we use the sampling 100 
power of aMD simulations to reveal the time-dependent conformational changes in the 101 
homology-modelled multidrug efflux pump AcrB from K. pneumoniae (SI), in interaction 102 
with Phenylalanyl-arginine-β-naphthylamide (PAβN), an inhibitor and modulator of AcrB7,53, 103 
and tetracycline (TET), a substrate for the transporter (Fig. 2) after generating the starting 104 
complexes by molecular docking. Principal component analysis (PCA) has been used to 105 
investigate the correlations among various important regions of the complexes in the course 106 
of aMD simulations and to distinguish between different conformational states. 107 
 108 
Results and Discussion 109 
Structures of the complexes. Fig. 1 shows the generated structure and important parts of 110 
AcrB transporter for Klebsiella pneumoniae by homology modelling using Swiss Model 111 
webserver with sequence identity 91.6% against the template, crystal structure of AcrB of 112 
Escherichia coli (PDB id code 4DX5). The trimer of the AcrB protein was obtained as the final 113 
model from homology modelling in a 3D PDB structure format. The template that was used 114 
for the homology modelling was a monomer structure and, therefore, the generated model 115 
was also a monomer structure. The assembly procedure was performed using the Accelrys 116 
discovery studio. The accuracy and validity of the generated AcrB model was examined in 117 
detail, and was shown in the different panels of Fig. S2. According to the SMINA molecular 118 
docking results, the location for the binding of PAβN to the protein structure was identified 119 
in the multisite binding pocket within the binding protomer of the transporter (Fig. 3). The 120 
docked complex of PAβN-AcrB was comparable to the previous structures determined for 121 
ligand-bound AcrB by Nakashima et al24.  Only one PAβN was bound to the binding 122 
monomer of homotrimer, and it was bound only to the multi-binding site. Also, other 123 
favorable docked poses showed that PAβN could bind to the access monomer of the AcrB 124 
homotrimer, which suggests that PAβN could be forced to pass through the path, during the 125 
dynamic of the efflux process, by a transient conformational change from the access form to 126 
the binding form, and PAβN would move to the gate of the distal pocket in the binding 127 
state. There were strong hydrophobic interactions between PAβN and Phe616 of AcrB which 128 
is located at the tip of the hairpin-like G-loop and forms a partition between the proximal 129 
binding pocket and distal binding pocket at the top of the channel between the two pockets. 130 
GOLD molecular docking of PAβN and TET to the located binding site by SMINA also showed 131 
that the affinity of PAβN to the AcrB transporter (binding energy -39.9 kcal/mol and score 132 
37.3) is much more favourable over TET (binding energy -25.6 kcal/mol and score 22.2). Phe-133 
cluster residues, including Phe136, Phe178, Phe616, Phe627 and Phe665, provided effective 134 
Pi interactions between the ligand and the transporter. These strong interactions resulted in 135 
higher score and favourable docking energy.  136 
 137 
Important regions of AcrB involved in interaction with ligands. Table 1 shows the residues 138 
of AcrB that interact with the ligand during the course of the simulation.  They have been 139 
marked by sequence alignment of AcrB K. pneumoniae to the solved-structure of AcrB from 140 
E. coli9,51. The matched amino acids in the alignment of AcrB sequences from E.coli and K. 141 
pneumoniae occupy the same locations in their corresponding PDB structures.  142 
Comparative binding of inhibitor and substrate. Molecular docking showed that PAβN was 143 
bound to the narrow channel under the G-loop. The naphthylamine moiety bonded to the 144 
bottom area of the distal binding site in interaction with Phe627. On the other side of the 145 
molecule, the arginine group was in the distal binding site in interaction with Gln176, with 146 
the phenylalanine group in interaction with Leu667 of proximal binding site (Fig. 3a and 147 
S3a). Tetracycline was in interaction with Ser134, a shared residue between the proximal 148 
and distal site, at the bottom of the narrow channel of the multi-binding site and mostly 149 
toward the distal pocket (Fig. 3d and S3d).  150 
The average structure extracted from cMD simulations showed that the naphthylamine 151 
moiety, phenylalanine and arginine groups of PAβN were bound to Phe136, Ph614 and 152 
Lys292 respectively, all in the distal binding site (Fig. 3b and S3b). It appeared that PAβN 153 
stayed in the hydrophobic site of the distal pocket. In contrast, tetracycline was found in 154 
interaction with Phe614, Tyr327 of the distal binding site and Phe616 of G-loop between the 155 
distal and proximal sites (Fig. 3e and S3e), which means the antibiotic failed to stay in the 156 
hydrophobic pocket.  157 
The monitoring of the interaction energy between the ligands and the amino acid residues 158 
of multi-binding site in AcrB, during the course of cMD by extracting the structures every 10 159 
ns, showed that the stability of PaβN-AcrB complex  is higher compared to tetracycline-ACrB 160 
complex. , There are at least three responsive amino acid Phe136, Phe616 and Phe627 with 161 
favorable interaction energy that could be observed in all 10 ns panels, whereas there is just 162 
one common responsive residue Phe614 during the cMD in the case of tetracycline (Table 163 
S1). 164 
At the end of the simulation, the results in the average structure extracted from aMD 165 
simulations indicated that the naphthylamine moiety of PAβN was still in interaction with 166 
Tyr327 and the phenylalanine moiety was in contact with Phe616 and Phe178 of the 167 
hydrophobic groove, in the distal binding site (Fig. 3c and S3c). Tetracycline, which was 168 
bound to a residue of the distal pocket, Phe614, was mostly in interaction with the residues 169 
of G-loop, Gly615, Phe616 and Ala617, as well as a residue from the proximal site, Leu667 170 
(Fig. 3f and S3f). This data suggests that PAβN could effectively interact with the 171 
hydrophobic groove of the distal pocket, as expected of a potential efflux pump inhibitor, 172 
which, by peripherally binding to the hydrophobic trap, could occlude the passageway and 173 
consequently interfere with the binding of the other compounds2,50,51. On the other hand, 174 
tetracycline formed weaker interactions with the hydrophobic pocket during the course of 175 
the simulation, which would eventually result in efflux through the transporter. This results 176 
in a good agreement with what Kinana and coworkers showed regarding the effects of 177 
various amino acids of binding pocket in substrate binding54.The monitoring of the 178 
interaction energies between the ligands and the key amino acid residues of multi-binding 179 
site in AcrB, during the course of aMD by extracting the average structures (Table S2), 180 
showed that the stability of PaβN-AcrB complex is higher compared to TET-AcrB complex. 181 
There were three amino acids that formed favourable interactions with PaβN compared to a 182 
single amino acid that interacted with Tetracycline during the course of the simulation. 183 
(Table S3).”. 184 
Monitoring the distances between the ligands and some of the key residues of the multi-185 
binding site of AcrB (Fig. S4) showed that, in the case of PAβN, the distances reach a steady 186 
state very soon via tight binding of the ligand to the deep hydrophobic groove, but for 187 
tetracycline they are fluctuating and variable, which means the ligand formed transient 188 
interactions moving around the multi-binding site. These results are in a good agreement 189 
with the multisite-drug-oscillation hypothesis Yamaguchi and co-workers for AcrB8. 190 
According to this hypothesis, the substrate is oscillating and may be just occluded in the 191 
distal pocket without a specific binding site, as we observed that tetracycline oscillates in 192 
the AcrB multibinding site in the spacious drug binding pocket. Also, it can explain the 193 
difference in the drug specificity in a certain exporter like AcrB, where tetracycline is 194 
exported and PAβN is not exported. 195 
 196 
Binding free energy. cMD simulations followed by calculation of the relative binding free 197 
energy of the inhibitor and substrate. Table 2 summarizes the calculated values of the 198 
different energy contributions to the relative binding free energy. The calculated binding 199 
free energy of tetracycline -11 kcal/mol is notably weaker than PAβN with -28 kcal/mol. The 200 
GB approach that resulted in a slightly lower binding energy for both substrate and inhibitor 201 
still suggests a more favorable complex in PAβN-bound state. It implies PAβN formed a 202 
stable complex that could inhibit the transporter, and that tetracycline is highly likely to end 203 
up being pumped out due to the weaker interaction.  204 
 205 
The entropy contribution in ligand binding was calculated to determine the absolute binding 206 
free energy and dissociation constant for the systems. The calculated values clearly show 207 
that the tendency of tetracycline is to be dissociated from the complex, but that PAβN is 208 
likely to remain as a complex with AcrB owing to its favourable free energy of binding. Also, 209 
comparison of the value of Kd in interaction of PAβN with AcrB (1.5×10-17) and AdeB (4.9×10-210 
6) in our recent study55 showed more binding strength and affinity of the inhibitor to the 211 
AcrB transporter over AdeB. This suggests that PAβN is an effective inhibitor of AcrB and 212 
explains why it does not inhibit the AdeB efflux pump. 213 
 214 
 215 
Principal component analysis. After running aMD simulations, PCA was performed to 216 
characterize the conformational transitions in the AcrB transporter, modulated by different 217 
ligands, with different roles as the potent inhibitor and substrate. The dendrogram data (Fig. 218 
S5) appeared to fall into six and seven clusters for PAβN- and TET- complexes, respectively, 219 
and the PCA plots are coloured to show this. By considering six and seven clusters in PAβN- 220 
and TET- complexes respectively, it can be seen that AcrB in complex with inhibitor has 221 
different dynamics and functions compared to the AcrB in complex with the substrate.   222 
 223 
 224 
 225 
Figs 4-6 show conformer plots that display the relationships between different conformers, 226 
highlighting the major differences between structures and enabling the interpretation and 227 
characterization of multiple inter-conformer relationships. They have been generated in 228 
three different panels for diverse protomers in AcrB; Access (loose)/ Binding (tight)/ 229 
Extrusion (open) subunits. PCA highlights that PAβN- and TET-bound conformations are not 230 
only different in the binding protomer (Fig. 4) but also that they are completely diverse in 231 
their extrusion and access conformations (Fig. 5 and 6). In addition, substrate-bound 232 
structures are different from inhibitor-bound ones, in general, as they possess diverse 233 
conformer graphs with diverse conformational clustering. 234 
 235 
The last row in the conformer graphs of Figs 4-6 is the eigenvalue spectrum obtained from 236 
the principal component analysis of the computationally determined conformers. The 237 
magnitude of each eigenvalue is expressed as the proportion of the total variance (mean-238 
square fluctuation) captured by the corresponding eigenvector. Labels on each point 239 
indicate the cumulative sum of variance accounted for by a particular eigenvector and its 240 
preceding eigenvectors. 241 
 242 
The fluctuations captured by the first principal component were visualized as a trajectory 243 
for each complex. They were generated as movies in PyMOL visualizer software for PAβN-244 
bound (Mov S1) and TET-bound (Mov S2) transporters. The movies show a different motion 245 
in AcrB transporter in interaction with different compounds applied in this study. There is 246 
another twist in the transmembrane domain of PAβN-bound transporter compared to TET-247 
bound transporter, so the observed motion in AcrB-TET complex is not present in AcrB- 248 
PAβN complex. Also, movies S3 and S4 were generated to show the dynamics of the AcrB 249 
pump in interaction with PAβN and TET respectively using extracted snapshots during the 250 
aMD simulations by VMD and the movie was created by VideoMach software. 251 
 252 
Discussion 253 
We examined the binding of PAβN and tetracycline to the multi binding pocket of the 254 
binding protomer of AcrB, at first by blind docking with the program Autodock SMINA and 255 
then using GOLD56 flexible molecular docking in the SMINA-located site. The study was 256 
followed by conventional molecular dynamics simulations combined by accelerated 257 
molecular dynamics, for a whole model of AcrB transporter used to study the dynamics of 258 
all the three protomers of the pump. 259 
The accurate computational observation and direct assessment of functionally important 260 
protein dynamics and conformations, without any timescale limitations, were performed 261 
using an accelerated molecular dynamics simulation approach, by simulating the transition 262 
between minima of different potential energy. By this approach, we have gained insight to 263 
the comparative function of AcrB in interaction with its substrate or inhibitor. The results 264 
show that the motion of the transporter was induced by the ligand in the interaction with 265 
the multi-binding site. The induced motion is ligand-dependent, which means it is different 266 
for the two bound compounds. The different dynamics for PaβN -bound form of AcrB 267 
compared to the Tet-bound form is likely to affect the rotating mechanism typically 268 
observed for AcrB transporter. This type of motion dependency has implications for 269 
understanding the ligand binding mechanisms in the AcrB tripartite efflux pump.  270 
In agreement with Nikaido et al., whose work showed that the binding position of the 271 
naphthylamine moiety of PAβN is the reason why it produces efflux inhibition50,51, the 272 
results of this study showed a strong interaction between naphthylamine moiety of PAβN 273 
and the hydrophobic trap of distal binding site. Nikaido et al. also suggested that the largest 274 
fraction of the binding energy comes from the trap and PAβN interacts strongly with  the 275 
trap51. Similarly, binding free energy calculations showed a very favorable free energy of 276 
binding for PAβN in interaction with AcrB. In addition, monitoring of the interaction energy 277 
between this inhibitor and key residues of binding site indicate that Ala132, Ala617, Ser134, 278 
Phe627, Phe136 and Phe616 in AcrB-PAβN complex with the most favorable energy of 279 
interaction mostly belong to the hydrophobic trap. 280 
 281 
Nikaido et al. computationally showed that PAβN as an inhibitor of AcrB from E.coli tends to 282 
move out the distal pocket at least partially, getting into contact with G-loop, and is thought 283 
to control the access of substrates to distal pocket2. In another study they showed that the 284 
mode of binding of PAβN to AcrB affects  the efflux of other compounds50. In addition, they 285 
experimentally and computationally showed that PAβN inhibited the efflux of other drugs 286 
by binding to the hydrophobic trap of the distal binding pocket, and also by interfering with 287 
the binding of other drug substrates to the upper part of the binding pocket. Our results 288 
also showed that PAβN occludes the channel by sticking to the hydrophobic binding pocket 289 
and interaction with other residues within the multi-binding site. Occlusion of the binding 290 
protomer affects the regular dynamics and allosteric switching motions of three protomer 291 
of the transporter. Consequently, normal rotatingmotion which leads to the extrusion of the 292 
compound could be corrupted. Abnormality in the motion of the transporter causes 293 
dramatic changes to the pump’s compound extrusion ability. The new dominant dynamics 294 
induced by the interaction of the inhibitor with the transporter, by blocking the binding 295 
monomer, corrupt the switching of the functional dynamics and prevent the transporter 296 
from extruding the compounds. It seems that the efflux pump works by a ligand-dependent 297 
dynamics approach that fully affects the functional features of the transporter. Another 298 
study on AcrB of E. coli showed that the assembly of the RND-type efflux systems is 299 
dynamically regulated in response to external stimuli57. 300 
 301 
This study showed AcrB could adopt different dynamics when it interacts with its substrate 302 
Tetracycline compared to the inhibitor PaβN-bound form. The simulation data suggests the 303 
correlations among the distal and proximal pockets of the multi-binding site, Phe cluster and 304 
cleft during the inhibitor binding event could result in the inhibition of the rotating 305 
mechanism and prevent the exporter from extruding any other substrates, leading to the 306 
inhibition of the tripartite pump.  The information obtained from the study will contribute 307 
to the design of new, effective and selective efflux pump inhibitors that could play key roles 308 
in interrupting the rotating mechanism and allosteric conformational changes that could 309 
reverse antimicrobial resistance.2 310 
 311 
Methods: 312 
cMD and aMD simulations were performed using the program AMBER 1258. MD simulations 313 
started from the docked structures, obtained from blind docking by AutoDock SMINA59, 314 
which followed by flexible docking using the GOLD56 program. MD simulations of efflux 315 
pump complexes have been carried out without the lipid bilayer due to the size of the efflux 316 
pump systems. Vargiu2 and Kinana50 showed that the results for systems with and without 317 
the lipid bilayer are essentially the same and equally valid. However, the transporter was 318 
not truncated  and the whole trimeric protein structure was used in this study. In this study, 319 
the power of GPU acceleration combined with the sampling power of aMD raising minima, 320 
were used to study conformational transitions that occur in AcrB in interaction with 321 
substrate and inhibitor, separately. Also, the CUDA implementation of PMEMD was used to 322 
carry out the simulations on GPUs.  323 
 324 
Generating the structures. The structure of the Klebsiella pneumoniae AcrB transporter was 325 
generated by homology modelling using Swiss Model webserver, by applying Uniprot code 326 
Q93K40 as the amino acid sequence. The template was AcrB of Escherichia coli, with PDB ID 327 
code 4DX5 and resolution 1.9 Å. The sequence identity between the target and template 328 
was 91.6%. The accuracy and validity of the generated AcrB model was examined by 329 
Phyre260 and the MPI Bioinformatics toolkit61. Phenylalanyl-arginine-β-naphthylamide 330 
(PAβN) and tetracycline (TET) PDB structures were generated by Chem3D 15.0. All the 331 
receptor and ligand structures were minimized by the SYBYL program. 332 
Molecular docking. The starting structures for running simulations were obtained by 333 
molecular docking of the ligands to the AcrB transporter. The orientation of the ligands 334 
within the multi-binding site of the binding protomer was taken from docking calculations 335 
performed with the AutoDock SMINA package59 through blind molecular docking, to find the 336 
cavity for ligands with the best affinity among all the probable ones. All the parameters 337 
were kept at their default values for running SMINA. 338 
  339 
Then, an evaluated flexible molecular docking was performed using GOLD56 molecular 340 
docking into the SMINA-located binding site. The Genetic algorithm (GA) is used in GOLD 341 
ligand docking to examine the ligand conformational flexibility, along with the partial 342 
flexibility of the protein. The maximum number of runs was set to 20 for each compound, 343 
with the default parameters (100 population size, 5 for the number of islands, 100,000 344 
number of operations and 2 for the niche size). Default cut off values of 2.5Å (dH-X) for 345 
hydrogen bonds and 4.0 Å for van-der-Waals distance were used. When the solutions 346 
attained RMSD values within 1.5 Å, GA docking was terminated. 347 
 348 
Molecular dynamics (MD) simulations. In this stage, the method section includes (i) 349 
preparatory energy minimizations, heating the system, cMD equilibration, (ii) building a 350 
simulation environment suitable for aMD simulations. 351 
 352 
cMD simulations were performed using the AMBER 12 package program58. A time step of 2 353 
fs was used. Periodic boundary conditions were used, and electrostatic interactions were 354 
treated using the particle-mesh Ewald method, with a real-space cutoff of 12 Å and a grid 355 
spacing of 1 Å per grid point in each dimension. The van der Waals interactions were 356 
modeled with a Lennard–Jones potential, using a 12 Å cutoff. The simulations were 357 
performed in NPT ensemble, which means the temperature and pressure conditions were 358 
constant, and the temperature was kept at 300 K by applying the Langevin thermostat to all 359 
heavy atoms, with the Langevin damping constant set to 5 ps-1. The pressure was kept at 1 360 
atm using the isotropic position scaling protocol used in AMBER.  361 
 362 
The minimization was performed in two phases, and each phase was performed in two 363 
stages. In the first phase, ions and all water molecules were minimized for 2500 cycles of 364 
steepest descent followed by 2500 cycles of conjugate gradient minimization. Afterward, 365 
the entirety of the systems were minimized for a total of 10000 cycles without restraint, 366 
wherein 5500 cycles of steepest descent were followed by 4500 cycles of conjugate gradient 367 
minimization. After minimizations, the systems were heated for 500 ps while the 368 
temperature was raised from 0 to 300 K, and then equilibration was performed without a 369 
restraint for 1000 ps while the temperature was kept at 300 K. Sampling of reasonable 370 
configurations was conducted by running 100 ns simulations for each system. 371 
 372 
Using the relaxed starting structure, obtained from cMD, the necessary information was 373 
calculated to set the necessary aMD parameters. Calculations of the added values for 374 
performing aMD simulations were shown at the end of the SI file as a note. From cMD run, 375 
we obtained the average total potential energy of -54,6820 and -59,5545 kcal/mol, and 376 
average dihedral energy of 32671 and 32605 kcal/mol for AcrB-PAβN and AcrB-TET systems, 377 
respectively. Using this information, and considering AcrB has 3093 residues and that the 378 
two mentioned complex systems have 196809 and 211425 atoms, respectively, the aMD 379 
parameters were calculated; Average total potential energy threshold (EthreshP) were 380 
obtained as -515,331 and -561,717  kcal/mol; Inverse strength boost factor for the total 381 
potential energy (alphaP) were obtained 31,489 and 33,828 kcal/mol; Average dihedral 382 
energy threshold (EthreshD) were obtained 45,047 and 44,961 kcal/mol; Inverse strength 383 
boost factor for the dihedral energy (alphaD) were obtained 2,475 and 2,471 kcal/mol, for 384 
AcrB-PAβN and AcrB-TET systems respectively. Then, the full 200ns aMD simulations were 385 
run for each system. 386 
 387 
Postprocessing analyses: MM-PBSA/MM_GBSA calculation. The free energy of binding of 388 
the compounds to AcrB was evaluated by means of the molecular mechanic energies 389 
combined with the Poisson–Boltzmann and generalized Born and surface area continuum 390 
solvation (MM/PBSA/MM/GBSA) postprocessing methods62,63. In these method, the binding 391 
free energy of each compound is evaluated as 392 
 393 
(1) ΔGbind = Gcom – (Grec + Glig) 394 
 395 
with Gcom, Grec, and Glig being the absolute free energies of complex, receptor, and ligand, 396 
respectively, averaged over the equilibrium trajectory of the complex (single-trajectory 397 
approach). According to these schemes, the free-energy difference can be decomposed as 398 
 399 
(2) ΔGbind = ΔEMM + ΔGsolv − TΔSconf  400 
 401 
where ΔEMM is the difference in the molecular mechanics energy, ΔGsolv is the solvation-free 402 
energy, and ΔSconf is the solute conformational entropy. The first two terms were calculated 403 
with the following equations:  404 
 405 
(3) ΔEMM = ΔEbond + ΔEangle + ΔEtorsion + ΔEvdw + ΔEelec 406 
(4) ΔGsolv = ΔGsolv,p + ΔGsolv,np 407 
 408 
EMM includes the molecular mechanics energy contributed by the bonded (Ebond, Eangle, 409 
and Etorsion) and nonbonded (Evdw and Eele, calculated with no cutoff) terms of the force field. 410 
ΔGsolv is the solvation-free energy, which can be modeled as the sum of an electrostatic 411 
contribution (ΔGsolv,p, evaluated using the MMGBSA or MM-PBSA approach) and a nonpolar 412 
one (ΔGsolv,np = γΔSA + b, proportional to the difference in solvent-exposed surface area, 413 
ΔSA). 414 
 415 
In this approach for the fully equilibrated structures (Fig. S6), 20 snapshots were collected 416 
from the last 200 ps of cMD simulations of complex systems for post processing analysis of 417 
free energy calculation. The RMSD of the ligands (Fig S7) with respect to the last 418 
conformation of the corresponding ligands sampled during the MD were calculated which 419 
showed the ligands in complex with the systems reached steady state at the end of the 420 
simulation The ΔGPB term was calculated by solving the finite-difference Poisson-Boltzmann 421 
equation using the internal PBSA program. The SCALE value was set to 2. The Parse radii 422 
were employed for all atoms64. The solvent probe radius was set at 1.4 Å (with the radii in 423 
the prmtop files). MM-PBSA running was performed with the pbsa module (PROC=2). The 424 
value of the exterior dielectric constant was set at 80, and the solute dielectric constant was 425 
set at 165. The nonpolar contribution was determined on the basis of the solvent accessible 426 
surface area (SASA) using the LCPO method 66 and CAVITY-OFFSET set at 0.00. 427 
 428 
Finally, the conformational entropy contribution, to estimate the absolute binding free 429 
energy, was calculated through normal-mode analysis using the ‘nmode’ module of AMBER. 430 
 431 
Postprocessing analyses: Analysis of protein conformational change using principal 432 
component analysis (PCA). The original trajectory files produced by aMD were significantly 433 
large, and we can't include them to Bio3d package installed in R program due to space 434 
limitations, so the trajectories in each aMD simulations were down sampled with an interval 435 
of 100. The points represented in the conformer plots were computationally clustered and 436 
colored by the cluster. This was performed by creating a distance matrix of the principal 437 
components of interest.  438 
 439 
PCA reduces the dimensionality of large data sets by calculating a covariance matrix and its 440 
eigenvectors. Vectors with the highest eigenvalues become the most significant principal 441 
components. When principal components are plotted against each other, similar structures 442 
cluster. Each cluster then theoretically shows a different protein conformational state. To 443 
avoid sample noise from random fluctuations48,67, following aMD simulations of the AcrB 444 
transporter, the PCA was calculated only for Cα atoms. Then, each protomer was selected in 445 
a separate PCA analysis, which was a good discriminator of conformations. 446 
 447 
With the Bio3D package installed in R, the plot command has been overloaded to create a 448 
default PCA plot with four graphs. Three are the z-scores of the first three principal 449 
components plotted against each other in two dimensions. The last is a scree plot showing 450 
how much of the variance of the data set is captured by each principal component. 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
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  672 
Tables 673 
Table 1. The key residues, forming different important regions of AcrB involved in 674 
interaction with ligands or functional dynamics of the pump.  Numbering is according to the 675 
amino acids’ positions in the K. pneumoniae  676 
 677 
Region K. pneumoniae AcrB  
Lining residues 
 
Proximal  
Binding site 
S79, T91, S134, S135, K292, L572, M574, 
Q576, F616, T623, M661, F663, F665, 
N666, L667, L673, T675, D680, R716, N718, 
E825 
 
Distal  
binding site 
S46, Q89, S128, E130, S134, F136, Q176, 
L177, F178, S180, E273, N274, D276, I277, 
G290, Y327, L572, F609, V611, F614, F616, 
R619, F627 
Cleft F663, F665, L667, R716, L827 
G-loop/Phe-loop G615, F616, A617, G618 
G-loop tip Phe616 
Postulate gate Q124, Y757 
 678 
 679 
Table 2. Calculated energy contributions to form the AcrB−PAβN and AcrB−TET complexes 680 
(kcal/mol) and inhibition constants (Kd in Molar) with standard errors of the mean (in 681 
parentheses) after cMD 682 
 683 
Energy distributions AcrB-PAβN AcrB-TET
ΔEele  -16.7 (2.1) -20.1 (2.2)
ΔEvdw -49.2 (2.0) -41.6 (1.1)
ΔEsol  37.8 (3.3)  49.7 (3.5)
ΔGPB -28.1 (2.9) -11.9 (1.9)
ΔGGB -35.9 (2.3) -16.3 (2.3)
-TΔS 18.7 18.9
ΔGbind -9.4 (0.7) 6.9 (0.5)
Kd * 1.4×10-7 1.2×105
Kd (Bulk)** 8.4×1017 7.3×1029
*Kd obtained by using ΔG = RT ln Kd formula 684 
**Calculated by considering Avogadro’s number 685 
 686 
  687 
Figures 688 
 689 
Figure 1. a) The proposed homotrimer model structure of the AcrB efflux pump transporter 690 
in complex with PAβN. It represents the structure that was obtained after carrying out the 691 
homology modelling, minimization and equilibration. The full-space complete homotrimer 692 
structure of AcrB has been shown on the right side of the picture, and each subunit has 693 
been represented by different colours; The binding site in binding monomers determined by 694 
SMINA molecular docking somewhere close to the distal pocket has been represented by a 695 
black circle b) Tetracycline in the multi-binding sites within the binding protomer of the AcrB 696 
transporter. 697 
 698 
 699 
 700 
Figure 2.  Chemical structures of the compounds, PAβN and Tetracycline, used in this study 701 
 702 
Figure 3. 3D structures of PAβN (right column) and TET (left column) in the multi binding site 703 
of AcrB; a) after GOLD molecular docking, b) average structure after 100 ns cMD and c) 704 
average structure after 200 ns aMD.  705 
 706 
Figure 4. Row 1-3) Conformer plot of PCA data colored by cluster after calculation of cluster 707 
groups in the binding protomer of AcrB-PAβN (left panels) and AcrB-TET (right panels); Row 708 
4). The rank ordering of the eigenvalues of the covariance matrix. Eigenvalue spectrum: 709 
Results obtained from diagonalization of the atomic displacement correlation matrix of Cα 710 
atom coordinates from the first snapshot structures. Inset shows histograms for the 711 
projection of the distribution of structures onto the first six principal components. 712 
 713 
Figure 5. Row 1-3) Conformer plot of PCA data colored by cluster after calculation of cluster 714 
groups in access protomer of AcrB-PAβN (left panels) and AcrB-TET (right panels); Row 4) 715 
The rank ordering of the eigenvalues of the covariance matrix. Eigenvalue spectrum: Results 716 
obtained from diagonalization of the atomic displacement correlation matrix of Cα atom 717 
coordinates from the first snapshot structures. Inset shows histograms for the projection of 718 
the distribution of structures onto the first six principal components. 719 
 720 
 721 
Figure 6. Row 1-3) Conformer plot of PCA data colored by cluster after calculation of cluster 722 
groups in extrusion protomer of AcrB-PAβN (left panels) and AcrB-TET (right panels); Row 4) 723 
The rank ordering of the eigenvalues of the covariance matrix. Eigenvalue spectrum: Results 724 
obtained from diagonalization of the atomic displacement correlation matrix of Cα atom 725 
coordinates from the first snapshot structures. Inset shows histograms for the projection of 726 
the distribution of structures onto the first six principal components. 727 
